Letter to the Editor: Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease.
作者信息
Li Roger, Sylvester Richard, Dinney Colin P, Kamat Ashish M
机构信息
Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Formerly Department of Biostatistics, EORTC Headquarters, Brussels, Belgium.
出版信息
Bladder Cancer. 2017 Jul 27;3(3):147-148. doi: 10.3233/BLC-179020.
Abstract
摘要
相似文献
1
Letter to the Editor: Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease.致编辑的信：卡介苗（BCG）治疗非肌层浸润性膀胱癌失败：BCG无反应性疾病的数据驱动定义
Bladder Cancer. 2017 Jul 27;3(3):147-148. doi: 10.3233/BLC-179020.
2
Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder Cancer.卡介苗无应答非肌肉浸润性膀胱癌的新兴免疫治疗选择。
J Urol. 2019 Dec;202(6):1111-1119. doi: 10.1097/JU.0000000000000297. Epub 2019 May 1.
3
Bacillus Calmette-Guérin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease.卡介苗（BCG）治疗非肌层浸润性膀胱癌失败：BCG无反应性疾病的数据驱动定义
Bladder Cancer. 2016 Apr 27;2(2):215-224. doi: 10.3233/BLC-150039.
4
Construction of predictive models for cancer-specific survival of patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: results from a multicenter retrospective study.卡介苗治疗非肌层浸润性膀胱癌患者癌症特异性生存预测模型的构建：一项多中心回顾性研究结果
Jpn J Clin Oncol. 2014 Nov;44(11):1101-8. doi: 10.1093/jjco/hyu119. Epub 2014 Aug 19.
5
Bacillus Calmette-Guérin Salvage Therapy: Definitions and Context.卡介苗挽救治疗：定义与背景。
Urol Clin North Am. 2020 Feb;47(1):1-4. doi: 10.1016/j.ucl.2019.09.002.
6
Role of immunotherapy in bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.免疫疗法在卡介苗无反应性非肌肉浸润性膀胱癌中的作用。
Urol Oncol. 2018 Mar;36(3):103-108. doi: 10.1016/j.urolonc.2017.12.020. Epub 2018 Feb 9.
7
Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: Results from a randomized trial.卡介苗维持治疗在中高危非肌层浸润性膀胱癌经尿道膀胱肿瘤完全切除术后的作用不显著：一项随机试验的结果
Int J Urol. 2016 Oct;23(10):854-860. doi: 10.1111/iju.13167. Epub 2016 Jul 15.
8
Intravesical and alternative bladder-preservation therapies in the management of non-muscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin.卡介苗无反应的非肌层浸润性膀胱癌的膀胱内及其他膀胱保留疗法
Urol Oncol. 2016 Jun;34(6):279-89. doi: 10.1016/j.urolonc.2015.12.004. Epub 2016 Jan 14.
9
Contemporary cost-effectiveness analysis comparing sequential bacillus Calmette-Guerin and electromotive mitomycin versus bacillus Calmette-Guerin alone for patients with high-risk non-muscle-invasive bladder cancer.当代成本效益分析：比较序贯卡介苗和电动丝裂霉素与单独使用卡介苗治疗高危非肌层浸润性膀胱癌患者的效果
Cancer. 2014 Aug 15;120(16):2424-31. doi: 10.1002/cncr.28731. Epub 2014 Apr 18.
10
Adverse reactions related to treatment compliance during BCG maintenance therapy for non-muscle-invasive bladder cancer.非肌肉浸润性膀胱癌卡介苗维持治疗期间与治疗依从性相关的不良反应。
Jpn J Clin Oncol. 2013 Aug;43(8):827-34. doi: 10.1093/jjco/hyt086. Epub 2013 Jul 14.
本文引用的文献
1
Bacillus Calmette-Guérin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease.卡介苗（BCG）治疗非肌层浸润性膀胱癌失败：BCG无反应性疾病的数据驱动定义
Bladder Cancer. 2016 Apr 27;2(2):215-224. doi: 10.3233/BLC-150039.
2
Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group.非肌层浸润性膀胱癌的定义、终点指标及临床试验设计：国际膀胱癌小组的建议
J Clin Oncol. 2016 Jun 1;34(16):1935-44. doi: 10.1200/JCO.2015.64.4070. Epub 2016 Jan 25.
3
Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG.膀胱内卡介苗治疗患者后膀胱癌疾病状态的阐明
Bladder Cancer. 2015 Mar 30;1(1):29-30. doi: 10.3233/BLC-159002.
4
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†.肾细胞癌临床试验中事件时间终点定义指南：DATECAN 项目的结果†。
Ann Oncol. 2015 Dec;26(12):2392-8. doi: 10.1093/annonc/mdv380. Epub 2015 Sep 14.
5
Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance.EORTC-GU 癌症组维持卡介苗治疗中高危 Ta、T1 膀胱乳头状癌的随机研究最终结果：三分之一剂量与全剂量和 1 年与 3 年维持治疗。
Eur Urol. 2013 Mar;63(3):462-72. doi: 10.1016/j.eururo.2012.10.039. Epub 2012 Nov 2.
6
Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder.EORTC 泌尿生殖系统肿瘤组随机 3 期研究 30911 的长期疗效结果，比较表柔比星、卡介苗和卡介苗联合异烟肼膀胱内灌注治疗中高危期 TaT1 尿路上皮膀胱癌患者的疗效。
Eur Urol. 2010 May;57(5):766-73. doi: 10.1016/j.eururo.2009.12.024. Epub 2009 Dec 18.
7
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).实体瘤新的疗效评价标准：修订的RECIST指南（第1.1版）
Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
8
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.辅助性乳腺癌试验中疗效终点标准化定义的提案：STEEP 系统。
J Clin Oncol. 2007 May 20;25(15):2127-32. doi: 10.1200/JCO.2006.10.3523.
9
Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer.卡介苗联合α-2B干扰素用于降低浅表性膀胱癌复发的全国多中心II期试验的最终结果。
Urol Oncol. 2006 Jul-Aug;24(4):344-8. doi: 10.1016/j.urolonc.2005.11.026.
Zotero 插件